Safety follow-up of SD-101 for epidermolysis bullosa
Part of Genetic & congenital, Skin clinical trials.
This study is a follow-up safety study for people who have already completed an earlier trial of SD-101 for epidermolysis bullosa (a condition causing fragile skin). It aims to check the long-term safety of the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed an earlier study of this treatment (the SD-007 study).
- You (or someone who helps care for you) must be willing to follow all study rules.
- If you are of childbearing age, you must not be pregnant, not be breastfeeding, and use an effective birth control method during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This study evaluates pz-cel, a personalized skin cell treatment for wounds caused by dystrophic epidermolysis bullosa (a genetic condition causing fragile skin). It provides access to the treatment when the manufactured product doesn't meet standard release, or for patients needing special access, and helps ensure its safety and effectiveness.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.